366 related articles for article (PubMed ID: 31534544)
1. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.
Zhao T; Bao Y; Gan X; Wang J; Chen Q; Dai Z; Liu B; Wang A; Sun S; Yang F; Wang L
Theranostics; 2019; 9(21):6175-6190. PubMed ID: 31534544
[No Abstract] [Full Text] [Related]
2. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
[TBL] [Abstract][Full Text] [Related]
3. QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis.
Zhao T; Zhou Y; Wang Q; Yi X; Ge S; He H; Xue S; Du B; Ge J; Dong J; Qu L; Wang L; Zhou W
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34036385
[TBL] [Abstract][Full Text] [Related]
4. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
[No Abstract] [Full Text] [Related]
5. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
[TBL] [Abstract][Full Text] [Related]
6. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
[TBL] [Abstract][Full Text] [Related]
7. PON1 hypermethylation is associated with progression of renal cell carcinoma.
Li X; Yu Q
J Cell Mol Med; 2019 Oct; 23(10):6646-6657. PubMed ID: 31400051
[TBL] [Abstract][Full Text] [Related]
8. Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response.
Bao Y; Yang F; Liu B; Zhao T; Xu Z; Xiong Y; Sun S; Qu L; Wang L
Br J Cancer; 2018 Aug; 119(4):450-461. PubMed ID: 30033448
[TBL] [Abstract][Full Text] [Related]
9. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals.
Zhai W; Li S; Zhang J; Chen Y; Ma J; Kong W; Gong D; Zheng J; Xue W; Xu Y
Mol Cancer; 2018 Nov; 17(1):157. PubMed ID: 30419914
[TBL] [Abstract][Full Text] [Related]
11. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
12. MiR-532-5p suppresses renal cancer cell proliferation by disrupting the ETS1-mediated positive feedback loop with the KRAS-NAP1L1/P-ERK axis.
Zhai W; Ma J; Zhu R; Xu C; Zhang J; Chen Y; Chen Z; Gong D; Zheng J; Chen C; Li S; Li B; Huang Y; Xue W; Zheng J
Br J Cancer; 2018 Aug; 119(5):591-604. PubMed ID: 30082686
[TBL] [Abstract][Full Text] [Related]
13. Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma.
Shang D; Han T; Xu X; Liu Y
Int J Clin Exp Pathol; 2015; 8(9):11140-8. PubMed ID: 26617834
[TBL] [Abstract][Full Text] [Related]
14. Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/ lysophosphatidic acid axis.
Huang KB; Pan YH; Shu GN; Yao HH; Liu X; Zhou M; Wei JH; Chen ZH; Lu J; Feng ZH; Chen W; Han H; Zheng ZS; Luo JH; Zhang JX
Cancer Lett; 2021 Dec; 523():121-134. PubMed ID: 34626691
[TBL] [Abstract][Full Text] [Related]
15. Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.
Shi H; Sun Y; He M; Yang X; Hamada M; Fukunaga T; Zhang X; Chang C
Oncogene; 2020 Jan; 39(3):530-545. PubMed ID: 31501521
[TBL] [Abstract][Full Text] [Related]
16. NT5E inhibition suppresses the growth of sunitinib-resistant cells and EMT course and AKT/GSK-3β signaling pathway in renal cell cancer.
Peng D; Hu Z; Wei X; Ke X; Shen Y; Zeng X
IUBMB Life; 2019 Jan; 71(1):113-124. PubMed ID: 30281919
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.
Mitsui Y; Hirata H; Arichi N; Hiraki M; Yasumoto H; Chang I; Fukuhara S; Yamamura S; Shahryari V; Deng G; Saini S; Majid S; Dahiya R; Tanaka Y; Shiina H
Oncotarget; 2015 Apr; 6(11):9577-91. PubMed ID: 25797254
[TBL] [Abstract][Full Text] [Related]
18. CircRNA_001895 promotes sunitinib resistance of renal cell carcinoma through regulation of apoptosis and DNA damage repair.
Tan L; Huang Z; Chen Z; Chen S; Ye Y; Chen T; Chen Z
J Chemother; 2023 Feb; 35(1):11-18. PubMed ID: 34927575
[TBL] [Abstract][Full Text] [Related]
19. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.
Du Z; Li L; Huang X; Jin J; Huang S; Zhang Q; Tao Q
Oncotarget; 2016 Apr; 7(16):21618-30. PubMed ID: 26943038
[TBL] [Abstract][Full Text] [Related]
20. Silencing of tumor-suppressive NR_023387 in renal cell carcinoma via promoter hypermethylation and HNF4A deficiency.
Zhou H; Guo L; Yao W; Shi R; Yu G; Xu H; Ye Z
J Cell Physiol; 2020 Mar; 235(3):2113-2128. PubMed ID: 31432508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
